Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study.

被引：4
|
作者：
Caffo, Orazio
Bria, Emilio
De Giorgi, Ugo
Tucci, Marcello
Galli, Luca
Fratino, Lucia
Rossetti, Sabrina
Iacovelli, Roberto
Lo Re, Giovanni
Mosillo, Claudia
Gasparro, Donatello
Guglielmini, Pamela Francesca
Damiani, Azzurra
Procopio, Giuseppe
De Lisi, Delia
Ruatta, Fiorella
Scagliarini, Sarah
Donini, Maddalena
Sperduti, Isabella
Basso, Umberto
机构：
[1] Santa Chiara Hosp, Med Oncol, Trento, Italy
[2] Univ Verona, Verona, Italy
[3] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy
[4] San Luigi Hosp, Orbassano, Italy
[5] Azienda Osped Univ Pisana, Pisa, Italy
[6] Natl Canc Ctr CRO, Aviano, Italy
[7] Ist Nazl Tumori Fdn G Pascale IRCCS, Div Med Oncol, Dept Uro Gynaecol Oncol, Naples, Italy
[8] Univ Verona, Azienda Osped Univ Integrata, Med Oncol, Verona, Italy
[9] Santa Maria Angeli Gen Hosp, Pordenone, Italy
[10] Sapienza Univ Rome, Policlin Umberto 1, Rome, Italy
[11] Azienda Osped Univ Parma, Parma, Italy
[12] SS Antonio & Biagio & Cesare Arrigo Gen Hosp, Oncol, Alessandria, Italy
[13] Azienda Osped Univ San Martino, Genoa, Italy
[14] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[15] Campus Bio Med Univ Rome, Dept Med Oncol, Rome, Italy
[16] Fdn Piemonte Oncol IRCCS, Med Oncol, Candiolo, Italy
[17] Cardarelli Hosp, Naples, Italy
[18] Osped Cremona, SC Oncol, Cremona, Italy
[19] Regina Elena Inst Canc Res, Biostat Unit, Rome, Italy
[20] Ist Oncol Veneto IOV IRCCS, Dept Clin & Expt Oncol, Med Oncol Unit, Padua, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.5030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5030
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
    William K. Oh
    Raymond Miao
    Francis Vekeman
    Jennifer Sung
    Wendy Y. Cheng
    Marjolaine Gauthier-Loiselle
    Ravinder Dhawan
    Mei Sheng Duh
    Medical Oncology, 2017, 34
  • [22] Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
    Oh, William K.
    Miao, Raymond
    Vekeman, Francis
    Sung, Jennifer
    Cheng, Wendy Y.
    Gauthier-Loiselle, Marjolaine
    Dhawan, Ravinder
    Duh, Mei Sheng
    MEDICAL ONCOLOGY, 2017, 34 (09)
  • [23] Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes.
    Maines, Francesca
    De Giorgi, Ugo
    Facchini, Gaetano
    Fratino, Lucia
    Gasparro, Donatello
    Alesini, Daniele
    Basso, Umberto
    Tucci, Marcello
    Ortega, Cinzia
    Scagliarini, Sarah
    Verderame, Francesco
    Barni, Sandro
    D'Angelo, Alessandro
    Vicario, Giovanni
    Donini, Maddalena
    Carrozza, Francesco
    Sava, Teodoro
    Sirotova, Zuzana
    Santini, Daniele
    Caffo, Orazio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [24] Oncological outcome of metastasis castration resistant prostate cancer (mCRPC) treated with new different agents sequencing in post-docetaxel: a retrospective study in Songklanagarind Hospital
    Chaokhamin, Isaris
    Bejrananda, Thanan Tanan
    Attawettayanon, Worapat
    Chalieopanyarwong, Virote
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 20 - 20
  • [25] Clinical outcomes of patients (pts) age 60 or younger treated with docetaxel (DOC) for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (CYCLOP study)
    Veccia, Antonello
    Ortega, Cinzia
    di Lorenzo, Giuseppe
    La Russa, Francesca
    Burgio, Salvatore Luca
    Facchini, Gaetano
    Messina, Caterina
    Sacco, Cosimo
    Spizzo, Gilbert
    Aieta, Michele
    Lodde, Michele
    Mansueto, Giovanni
    Zucali, Paolo A.
    D'Angelo, Alessandro
    Iacovelli, Roberto
    Massari, Francesco
    Morelli, Franco
    Procopio, Giuseppe
    Ruatta, Fiorella
    Caffo, Orazio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [26] Impact of new agents (NAs) on survival of metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A single-Institution retrospective analysis.
    Caffo, Orazio
    Kinspergher, Stefania
    Maines, Francesca
    Macrini, Sveva
    Veccia, Antonello
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [27] Treatment patterns in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (DOC)-based chemotherapy (CT): PROXIMA 1-year analysis
    Akaza, H.
    Procopio, G.
    Pripatnanont, C.
    Facchini, G.
    Fava, S.
    Wheatley, D.
    Leung, K. C.
    Butt, M.
    Silva, A.
    Castillo, L.
    Karavasilis, V.
    Hitier, S.
    Ecstein-Fraisse, E. B.
    Bensfia, S.
    Ozguroglu, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S492 - S493
  • [28] TREATMENT SEQUENCES, PATIENT CHARACTERISTICS, AND OVERALL SURVIVAL OF PATIENTS WITH POST-DOCETAXEL METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN THE COMMUNITY SETTING
    Oh, W. K.
    Miao, R.
    Duh, M. S.
    Vekeman, F.
    Sung, J.
    Cheng, W. Y.
    Gauthier-Loiselle, M.
    Fortier, J.
    Dhawan, R.
    VALUE IN HEALTH, 2016, 19 (03) : A139 - A139
  • [29] Biweekly cabazitaxel as a safe treatment option for metastatic castration resistant prostate cancer (mCRPC) patients post-docetaxel: Final analysis of Prosty II trial.
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Marttila, Timo
    Jekunen, Antti Pekka
    Hervonen, Petteri
    Klintrup, Katariina
    Kataja, Vesa V.
    Utriainen, Tapio
    Luukkaa, Marjaana
    Leskinen, Markku
    Pulkkanen, Kalevi
    Lehtinen, Ilari
    Taalikka, Mikko
    Kautio, Anna-Liisa
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?
    Van Praet, Charles
    Rottey, Sylvie
    Van Hende, Fransien
    Pelgrims, Gino
    Demey, Wim
    Van Aelst, Filip
    Wynendaele, Wim
    Gil, Thierry
    Schatteman, Peter
    Filleul, Bertrand
    Schallier, Denis
    Machiels, Jean-Pascal
    Schrijvers, Dirk
    Everaert, Els
    D'Hondt, Lionel
    Werbrouck, Patrick
    Vermeij, Joanna
    Mebis, Jeroen
    Clausse, Marylene
    Rasschaert, Marika
    Van Erps, Joanna
    Verheezen, Jolanda
    Van Haverbeke, Jan
    Goeminne, Jean-Charles
    Lumen, Nicolaas
    CLINICAL GENITOURINARY CANCER, 2017, 15 (04) : 502 - 508
12345